Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics

Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics

Background: Tocilizumab is a monoclonal antibody proposed to manage cytokine release syndrome (CRS) associated with severe COVID-19. Previously published reports have shown that tocilizumab may improve the clinical outcomes of critically ill patients admitted to the ICU. However, no precise data abo...

Full description

Bibliographic Details
Main Authors: Alyaa Elhazmi, Ahmed A. Rabie, Awad Al-Omari, Hani N. Mufti, Hend Sallam, Mohammed S. Alshahrani, Ahmed Mady, Adnan Alghamdi, Ali Altalaq, Mohamed H. Azzam, Anees Sindi, Ayman Kharaba, Zohair A. Al-Aseri, Ghaleb A. Almekhlafi, Wail Tashkandi, Saud A. Alajmi, Fahad Faqihi, Abdulrahman Alharthy, Jaffar A. Al-Tawfiq, Rami Ghazi Melibari, Yaseen M. Arabi
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Journal of Clinical Medicine
Subjects:
tocilizumab
COVID-19
outcome
propensity-matching
Online Access:https://www.mdpi.com/2077-0383/12/6/2301

Internet

https://www.mdpi.com/2077-0383/12/6/2301

Similar Items